Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic
Umut KalyoncuGulsan YavuzServet AkarTimucin KaşifogluGezmis KimyonÖmer KaradağHüseyin Ediz DalkılıçAli Ihsan ErtenliLevent KilicEmine Duygu ErsözlüCemal BeşHakan EmmüngilRıdvan MercanElif Durak EdibogluNilufer Alpay KanitezAbdulsamet ErdenSeda YurumezSuleyman Serdar KocaEmel Orge GonulluOrhan KücüksahinCoskun Belkıs NihanBurcu YagizSedat KirazPublished in: Turkish journal of medical sciences (2021)
Although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients discontinued bDMARDs within this period. The long-term effects of the pandemic should be monitored.